High-resolution genomic variation detection for leukemia research
Obtain a comprehensive picture of genetic variation for four key human genes using the GS GType TET2/CBL/KRAS Primer Set. Accurately identify variants associated with developmental defects, disease progression, and residual disease in a variety of leukemias and myeloid malignancies using next-generation deep sequencing of PCR amplicons. This complete solution includes primer sets, protocols, and dedicated analysis software, such as the 454 GS Amplicon Variant Analyzer software or JSI Medical Systemsí SeqNext Software.
- Ready-to-run assay optimized for use with GS Junior and GS FLX Systems
- Accurately discover and characterize known and unknown variants in human TET2, CBL, and KRAS genes, including SNPs, insertions and deletions
- Detect variants at high sensitivity
- Perform haplotyping with long, high quality sequencing reads
- Use dedicated analysis software and tools to easily proceed from nucleotide variations to biologically-relevant protein alterations
- Co-developed with and extensively tested at the MLL Munich Leukemia Laboratory, Munich, Germany
High Sensitivity Variant Detection for KRAS, TET2 and RUNX1 Genes
Figure: Distribution of variant frequency results from 10 PBMC-extracted genomic DNA samples with 14 known leukemia variants in the KRAS, RUNX1 and TET2 genes. Samples were independently prepared and sequenced in multiple tests (n=18 to 36) to demonstrate reproducibility. All variants were tested using Sanger sequencing to confirm variant content. 454 Sequencing Systems detected the nine variants also detected by Sanger sequencing, as well as five additional variants below the Sanger sequencing limit of detection.
|Product Name||Pack Size||Catalog Number||Type|
|GS GType TET2/CBL/KRAS Primer Set||1 kit (4 PCR plates with dried-down primers)||06500498001||Kit|
- GS GType TET2/CBL/KRAS & RUNX1 Primer Sets Flyer
- Application Note: Targeted Sequencing of Leukemia-Associated Genes using 454 Sequencing Systems
- Landscape of TET2 mutations in acute myeloid leukemia. Weissmann S et al. (2011) Leukemia ePub:
- TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Bacher U et al. (2011) British Journal of Haematology 156(1):67-75.
- The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Kohlmann A et al. (2011) Leukemia 25(12):1840-8.
- Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Grossmann V et al. (2011) Leukemia 25(5):877-9.
- Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure. Grossmann V et al.(2011) Leukemia 25(4):671-80.
- A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Grossmann V et al. (2011) Leukemia 25(3):577-60.
- Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Kohlmann A et al. (2010) J Clin Oncology 28(24): 3858-65.